ruxolitinib

English

Noun

ruxolitinib (uncountable)

1. (pharmacology) A medication belonging to the class of Janus kinase inhibitors, used for the treatment of several diseases including myelofibrosis and polycythemia vera.
   • 2015 July 14, Li Zhang, Handong Wang, Orazio Taglialatela-Scafati, “Multiple Mechanisms of Anti-Cancer Effects Exerted by Astaxanthin”, in Marine Drugs‎^[1], volume 13, →DOI:

     For example, Gallipoli et al. reported that combination of nilotinib with ruxolitinib could induce apoptosis in chronic myeloid leukemia (CML) stem cells through inhibiting JAK-2/STAT-5 signaling pathway.

   • 2021 December, Christine Liu, Jacqueline Kieltyka, Roy Fleischmann, Massimo Gadina, John J. O’Shea, “A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?”, in Arthritis & Rheumatology, volume 73, number 12, →DOI, page 2168:

     The first jakinib to enter clinical trials, initially for renal transplantation, was tofacitinib, which inhibits JAK1/JAK2/JAK3; however, ruxolitinib, a JAK1/JAK2 inhibitor, was the first agent to receive approval, as a treatment for myeloproliferative neoplasms that often exhibit gain-of-function JAK2 mutations.